5Tr1 Aptamer-Pegylated Liposomal Doxorubicin Enhances Cellular Uptake and Suppresses Tumour Growth by Targeting Muc1 on the Surface of Cancer Cells

5Tr1 Aptamer-Pegylated Liposomal Doxorubicin Enhances Cellular Uptake and Suppresses Tumour Growth by Targeting Muc1 on the Surface of Cancer Cells Publisher Pubmed

Moosavian SA¹ ; Abnous K² ; Akhtari J³ ; Arabi L¹ ; Gholamzade Dewin A⁴ ; Jafari M¹

Show Affiliations

1. Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
2. Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3. Immunogenetics Research Center, Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Mazandaran University of Medical Sciences, Sari, Iran
4. Department of Pharmaceutical Science, Faculty of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran

Source: Artificial Cells# Nanomedicine and Biotechnology Published:2018

Abstract

Employing targeting ligands with high affinity to tumour receptors is an important strategy to increase treatment efficacy. The use of aptamers as targeting agent is increasingly prevalent in drug delivery systems. Mucin1 (MUC1) is a glycoprotein that is over-expressed on the surface of several cancer cells and plays an important role in metastasis and invasion. 5TR1-aptamer is a DNA aptamer, which targets MUC1 receptors. The present study investigated the anti-tumour activity and therapeutic effectiveness of 5TR1-aptamer-PEGylated liposomal doxorubicin (PLD) delivery system in C26 tumour-bearing mice. The in vitro experiments demonstrated enhanced cytotoxicity and cellular uptake of PLD at the presence of 5TR1 aptamer into MUC1 + C26 cell line. Biodistribution study indicated that aptamer conjugation increased tumour accumulation of PLDs. Pharmacokinetic analysis showed despite higher clearance rate, selective delivery of doxorubicin to tumour tissue was increased in the 5TR1-Doxil group. In C26-bearing tumour mice, treatment with 5TR1-Doxil exhibited significant deceleration in tumour growth and enhanced survival. The results suggested that 5TR1 aptamer is promising ligand for active targeting which improves therapeutic efficiency of PLD in cancer therapy. © 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group.

Related Docs

View other Related Docs

1. Improved Drug Delivery and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin by Targeting Anti-Her2 Peptide in Murine Breast Tumor Model, European Journal of Pharmaceutical Sciences (2016)

2. What We Need to Know About Liposomes As Drug Nanocarriers: An Updated Review, Advanced Pharmaceutical Bulletin (2023)

3. Functionalized Liposomes As Drug Nanocarriers for Active Targeted Cancer Therapy: A Systematic Review, Journal of Liposome Research (2022)

4. Controlled Anti-Cancer Drug Release Through Advanced Nano-Drug Delivery Systems: Static and Dynamic Targeting Strategies, Journal of Controlled Release (2020)

5. Optimization of Docetaxel Loading Conditions in Liposomes: Proposing Potential Products for Metastatic Breast Carcinoma Chemotherapy, Scientific Reports (2020)

6. Liposome-Targeted Delivery for Highly Potent Drugs, Artificial Cells# Nanomedicine and Biotechnology (2017)

7. Therapeutic Efficacy of Cisplatin Thermosensitive Liposomes Upon Mild Hyperthermia in C26 Tumor Bearing Balb/C Mice, Molecular Pharmaceutics (2017)

8. Protein Corona Hampers Targeting Potential of Muc1 Aptamer Functionalized Sn-38 Core-Shell Nanoparticles, International Journal of Pharmaceutics (2015)

Experts (# of related papers)

View all Related Experts

Rassoul Dinarvand (8)

Seyed Mahdi Rezayat Sorkhabadi (6)

Style	Citing Format
MLA	Moosavian SA, et al.. "5Tr1 Aptamer-Pegylated Liposomal Doxorubicin Enhances Cellular Uptake and Suppresses Tumour Growth by Targeting Muc1 on the Surface of Cancer Cells." Artificial Cells# Nanomedicine and Biotechnology, vol. 46, no. 8, 2018, pp. 2054-2065.
APA	Moosavian SA, Abnous K, Akhtari J, Arabi L, Gholamzade Dewin A, Jafari M (2018). 5Tr1 Aptamer-Pegylated Liposomal Doxorubicin Enhances Cellular Uptake and Suppresses Tumour Growth by Targeting Muc1 on the Surface of Cancer Cells. Artificial Cells# Nanomedicine and Biotechnology, 46(8), 2054-2065.
Chicago	Moosavian SA, Abnous K, Akhtari J, Arabi L, Gholamzade Dewin A, Jafari M. "5Tr1 Aptamer-Pegylated Liposomal Doxorubicin Enhances Cellular Uptake and Suppresses Tumour Growth by Targeting Muc1 on the Surface of Cancer Cells." Artificial Cells# Nanomedicine and Biotechnology 46, no. 8 (2018): 2054-2065.
Harvard	Moosavian SA et al. (2018) '5Tr1 Aptamer-Pegylated Liposomal Doxorubicin Enhances Cellular Uptake and Suppresses Tumour Growth by Targeting Muc1 on the Surface of Cancer Cells', Artificial Cells# Nanomedicine and Biotechnology, 46(8), pp. 2054-2065.
Vancouver	Moosavian SA, Abnous K, Akhtari J, Arabi L, Gholamzade Dewin A, Jafari M. 5Tr1 Aptamer-Pegylated Liposomal Doxorubicin Enhances Cellular Uptake and Suppresses Tumour Growth by Targeting Muc1 on the Surface of Cancer Cells. Artificial Cells# Nanomedicine and Biotechnology. 2018;46(8):2054-2065.
BibTex	@article{ author = {Moosavian SA and Abnous K and Akhtari J and Arabi L and Gholamzade Dewin A and Jafari M}, title = {5Tr1 Aptamer-Pegylated Liposomal Doxorubicin Enhances Cellular Uptake and Suppresses Tumour Growth by Targeting Muc1 on the Surface of Cancer Cells}, journal = {Artificial Cells# Nanomedicine and Biotechnology}, volume = {46}, number = {8}, pages = {2054-2065}, year = {2018} }
RIS	TY - JOUR AU - Moosavian SA AU - Abnous K AU - Akhtari J AU - Arabi L AU - Gholamzade Dewin A AU - Jafari M TI - 5Tr1 Aptamer-Pegylated Liposomal Doxorubicin Enhances Cellular Uptake and Suppresses Tumour Growth by Targeting Muc1 on the Surface of Cancer Cells JO - Artificial Cells# Nanomedicine and Biotechnology VL - 46 IS - 8 SP - 2054 EP - 2065 PY - 2018 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract